Atlas Trials

PETHEMA Foundation

105 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch PETHEMA Foundation

RecordFirmDate
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) (NCT07478991)PETHEMA Foundation2026-07-02
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients (NCT07507760)PETHEMA Foundation2026-06-12
Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma (NCT07637526)PETHEMA Foundation2026-06-01
Treatment for Ph-negative ALL for Adults up to 65 Years (NCT07443592)PETHEMA Foundation2026-03-06
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) (NCT07045909)PETHEMA Foundation2025-06-30
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (NCT06574126)PETHEMA Foundation2024-09-30
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT06544785)PETHEMA Foundation2024-09-02
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL (NCT06175702)PETHEMA Foundation2023-12-25
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (NCT06282978)PETHEMA Foundation2023-11-23
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (NCT05849610)PETHEMA Foundation2023-09-21
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. (NCT05527340)PETHEMA Foundation2022-12-15
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain. (NCT05297240)PETHEMA Foundation2022-03-24
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT (NCT05218603)PETHEMA Foundation2021-11-30
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (NCT04802356)PETHEMA Foundation2021-04-07
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old (NCT04687761)PETHEMA Foundation2020-11-04
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment (NCT04112589)PETHEMA Foundation2019-12-26
Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia (NCT04230239)PETHEMA Foundation2019-12-26
Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia (NCT04178798)PETHEMA Foundation2019-12-09
A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers (NCT05541224)PETHEMA Foundation2019-11-01
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy (NCT04090736)PETHEMA Foundation2019-09-24
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) (NCT04107727)PETHEMA Foundation2019-09-05
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years (NCT03742297)PETHEMA Foundation2018-10-22
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma (NCT03589222)PETHEMA Foundation2018-07-15
REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia (NCT03742323)PETHEMA Foundation2018-07-01
PETHEMA-BLIN-01/PET069014 (BLIN-01) (NCT03523429)PETHEMA Foundation2018-06-30
Study of Prognostic Factors in Adult Lymphoblastic Lymphoma (NCT03571997)PETHEMA Foundation2018-06-15
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM) (NCT03477643)PETHEMA Foundation2018-04-27
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma (NCT03336073)PETHEMA Foundation2017-12-18
Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia. (NCT03311815)PETHEMA Foundation2017-10-06
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab (NCT03280160)PETHEMA Foundation2017-09-07
Next →

Track PETHEMA Foundation automatically

Every clearance here is in the API, with alerts when new ones post.